Clinical Trial News and Research

RSS

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

Remarkable vision improvements after gene therapy for inherited blindness

One year after a trio of young adults received gene therapy for an inherited form of blindness, researchers have documented that the patients are still experiencing the same level of remarkable vision improvements previously measured within weeks.

13 Aug 2009

Antigenics’ Oncophage cancer vaccine trial starts enrolling patients

Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage (vitespen) in combination with the standard of care - radiation therapy plus Temodar (temozolomide) - for newly diagnosed glioma patients.

13 Aug 2009

A rebounding biotechnology industry

Investors accurately forecasted the rebound of the biotechnology industry, but underestimated the degree to which positive clinical trial data would drive the sector higher, according to findings from an investor perception study released today by the Biotechnology Industry Organization (BIO) and Thomson Reuters.

12 Aug 2009

ADVENTRX Pharmaceuticals reports Q2 2009 financials

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the three and six months ended June 30, 2009.

12 Aug 2009

Transgenomic reports Q2 2009 financials

The Company reported a net loss of $730,000 or $0.01 per share for the second quarter of 2009 as compared to net income of $101,000 or $0.00 per share for the second quarter of 2008.

12 Aug 2009

Neurologix announces Q2 2009 financials

Neurologix, Inc. (OTCBB:NRGX) announced today its financial results for the second quarter and six months ended June 30, 2009.

12 Aug 2009

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.

12 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Neoprobe announces Q2 financials

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.

12 Aug 2009

Mediterranean diet associated with reduced Alzheimer’s risk

Both being more physically active and adhering to a Mediterranean-type diet appears to be associated with reduced Alzheimer’s risk, according to a new report in the August 12, 2009 issue of the Journal of the American Medical Association (JAMA).

11 Aug 2009

American Medical Alert Corp. reports Q2 2009 results

American Medical Alert Corp. (NASDAQ: AMAC) a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter and six months ended June 30, 2009.

11 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

10 Aug 2009

Stemcells, Inc. reports Q2 financials

Results for the quarter reflect the Company’s acquisition of the operations of Stem Cell Sciences Plc (SCS), a UK-based company focused on cell-based technologies for drug discovery and screening.

10 Aug 2009

New hope for sufferers of alpha-1 antitrypsin deficiency

Researchers at the University of Massachusetts Medical School and the University of Florida in Gainesville have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases, according to clinical trial findings slated to appear this week in the online early edition of the Proceedings of the National Academy of Science.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009